Brief: Summit Therapeutics Announces Opening Of Global Phase Ii Study Of Ivonescimab-Based Regimens In Advanced Clear Cell Renal Cell Carcinoma
Mon 12:33
BRIEF-Summit Therapeutics Announces Opening Of Global Phase Ii Study Of Ivonescimab-Based Regimens In Advanced Clear Cell Renal Cell Carcinoma Oct 19 (Reuters) - Summit Therapeutics Inc. SMMT.O:
SUMMIT THERAPEUTICS ANNOUNCES OPENING OF GLOBAL PHASE II STUDY OF IVONESCIMAB-BASED REGIMENS IN ADVANCED CLEAR CELL RENAL CELL CARCINOMA
SUMMIT THERAPEUTICS - PHASE II STUDY EVALUATES IVONESCIMAB ALONE AND WITH CADONILIMAB OR IPILIMUMAB IN ADVANCED CCRCC
Source text: ID:nBw2XMXxPa
Further company coverage: SMMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Summit Therapeutics
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
Brief: Summit Therapeutics Announces Opening Of Global Phase Ii Study Of Ivonescimab-Based Regimens In Advanced Clear Cell Renal Cell Carcinoma
Factbox: Major drugmakers turn to China for licensing deals
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination (updated)